These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12904137)

  • 1. Safety of the new generation recombinant factor concentrates.
    Schlesinger KW; Ragni MV
    Expert Opin Drug Saf; 2002 Sep; 1(3):213-23. PubMed ID: 12904137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
    Fukutake K
    Semin Thromb Hemost; 2000; 26(1):29-32. PubMed ID: 10805278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies.
    Limentani SA
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S81-4. PubMed ID: 7795145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 11. The promise of third-generation recombinant therapy and gene therapy.
    Manno CS
    Semin Hematol; 2003 Jul; 40(3 Suppl 3):23-8. PubMed ID: 14690065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant clotting factor concentrates.
    Lusher JM
    Baillieres Clin Haematol; 1996 Jun; 9(2):291-303. PubMed ID: 8800506
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.
    Franchini M; Makris M; Santagostino E; Coppola A; Mannucci PM
    Haemophilia; 2012 May; 18(3):e164-72. PubMed ID: 22250981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The choice of plasma-derived clotting factor concentrates.
    Mannucci PM
    Baillieres Clin Haematol; 1996 Jun; 9(2):273-90. PubMed ID: 8800505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current state of adverse event reporting in hemophilia.
    van Vulpen LF; Saccullo G; Iorio A; Makris M
    Expert Rev Hematol; 2017 Feb; 10(2):161-168. PubMed ID: 28013565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
    Schaub RG
    Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemophilia B: Christmas disease.
    Giangrande P
    Expert Opin Pharmacother; 2005 Aug; 6(9):1517-24. PubMed ID: 16086639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.